Pilot study protocol of a randomized controlled trial for the potential effects of creatine monohydrate on persistent post-concussive symptoms

Frontiers in Neurology

Neurology

Ronni Lykke Bødker¹  Michael Marcussen² 

[1] Commotio Denmark, Køge, Denmark;Department of Public Health, University of Southern, Odense, Denmark;Department of Public Health, University of Southern, Odense, Denmark;Research unit of Psychiatry, Region Zealand, Slagelse, Denmark;

关键词: concussion;    creatine monohydrate;    persistent post-concussive symptoms;    mild traumatic brain injury;    nutrition;    Rivermead post-concussion symptoms questionnaire;   

DOI  :  10.3389/fneur.2023.1209548

 received in 2023-04-20, accepted in 2023-06-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundMild traumatic brain injury or concussion is a global public concern, with an estimated annual incidence between 48 million and 96 million worldwide. It is a socioeconomical problem, and almost one-third of individuals with concussion suffer from severe persistent post-concussive symptoms (PPCS), with an increased risk of unemployment or terminating their studies. To date, no single treatment is available with guaranteed success. Creatine monohydrate (CrM) has shown potential as a treatment for post-concussive symptoms, having a positive impact on cognitive function, chronic fatigue, depression, and anxiety. The aim of this study is to examine the effect of CrM on PPCS assessed using the Rivermead Post-Concussion Symptoms Questionnaire (RPQ).MethodsThe study is designed as a double-blinded randomised controlled trial. Study participants are found through neurological outpatient clinics in Denmark or through social media. They will be between 25 and 35 years of age, will have suffered from PPCS for 6–12 months prior to inclusion, and will have no comorbidities. The participants will be randomly allocated to either an intervention group (INT), placebo group (PLA), or control group (CG). Baseline data will be collected immediately after inclusion, and the study period will be 7 weeks. Follow-up data will be collected 1 week after the end of the study period. The primary outcome of the study is changes in RPQ score. Changes in weight and training status will be adjusted for as potential confounders.Ethics and disseminationThis protocol is approved by the National Committee on Health Research (97508) and by the Danish Data Protection Agency 11.651. The investigators intend to submit their study findings for publication in peer-reviewed journals and disseminate the findings via presentation at academic meetings/conferences.Clinical Trial registration: NCT05562232, registered September 30, 2022.

【 授权许可】

Unknown   
Copyright © 2023 Bødker and Marcussen.